Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and Trends—An update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27.

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Cancer J Clin. 2023;73(1):17–48.

Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Global Health. 2020;8(8):e1027–37.

Article  PubMed  Google Scholar 

Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: burden and trends. Cancer Epidemiol Biomarkers Prev. 2017;26(4):444–57.

Article  PubMed  Google Scholar 

Kehm RD, Yang W, Tehranifar P, Terry MB. 40 years of change in Age- and Stage-Specific cancer incidence rates in US women and men. JNCI Cancer Spectr 2019;3(3).

Emilsson V, Ilkov M, Lamb JR, et al. Co-regulatory networks of human serum proteins link genetics to disease. Science. 2018;361(6404):769–73.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Schwenk JM, Omenn GS, Sun Z, et al. The human plasma proteome draft of 2017: Building on the human plasma PeptideAtlas from mass spectrometry and complementary assays. J Proteome Res. 2017;16(12):4299–310.

Article  PubMed  PubMed Central  CAS  Google Scholar 

International Human Genome Sequencing C. Finishing the euchromatic sequence of the human genome. Nature. 2004;431(7011):931–45.

Article  Google Scholar 

Lin H, Lee E, Hestir K, et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science. 2008;320(5877):807–11.

Article  PubMed  CAS  Google Scholar 

Williams SA, Kivimaki M, Langenberg C, et al. Plasma protein patterns as comprehensive indicators of health. Nat Med. 2019;25(12):1851–7.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Key TJ, Appleby PN, Reeves GK, Roddam AW. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol. 2010;11(6):530–42.

Article  PubMed  Google Scholar 

Mälarstig A, Grassmann F, Dahl L, et al. Evaluation of Circulating plasma proteins in breast cancer using Mendelian randomisation. Nat Commun. 2023;14(1):7680.

Article  PubMed  PubMed Central  Google Scholar 

Shu X, Bao J, Wu L, et al. Evaluation of associations between genetically predicted Circulating protein biomarkers and breast cancer risk. Int J Cancer. 2020;146(8):2130–8.

Article  PubMed  CAS  Google Scholar 

Song J, Yang H. Identifying new biomarkers and potential therapeutic targets for breast cancer through the integration of human plasma proteomics: a Mendelian randomization study and colocalization analysis. Front Endocrinol (Lausanne). 2024;15:1449668.

Article  PubMed  Google Scholar 

Papier K, Atkins JR, Tong TYN, et al. Identifying proteomic risk factors for cancer using prospective and exome analyses of 1463 Circulating proteins and risk of 19 cancers in the UK biobank. Nat Commun. 2024;15(1):4010.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Grassmann F, Mälarstig A, Dahl L, et al. The impact of Circulating protein levels identified by affinity proteomics on short-term, overall breast cancer risk. Br J Cancer. 2024;130(4):620–7.

Article  PubMed  CAS  Google Scholar 

Terry MB, Phillips KA, Daly MB, et al. Cohort profile: the breast cancer prospective family study cohort (ProF-SC). Int J Epidemiol. 2016;45(3):683–92.

Article  PubMed  Google Scholar 

Pharoah P, Day N, Duffy S, Easton D, Ponder B. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer. 1997;71:800–9.

Article  PubMed  CAS  Google Scholar 

Braithwaite D, Miglioretti DL, Zhu W, et al. Family history and breast cancer risk among older women in the breast cancer surveillance consortium cohort. JAMA Intern Med. 2018;178(4):494–501.

Article  PubMed  PubMed Central  Google Scholar 

Rinschen MM, Ivanisevic J, Giera M, Siuzdak G. Identification of bioactive metabolites using activity metabolomics. Nat Rev Mol Cell Biol. 2019;20(6):353–67.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wu HC, Lai Y, Liao Y, et al. Plasma metabolomics profiles and breast cancer risk. Breast Cancer Res. 2024;26(1):141.

Article  PubMed  PubMed Central  CAS  Google Scholar 

John E, Hopper J, Beck J, et al. The breast cancer family registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res. 2004;6(4):R375–89.

Article  PubMed  PubMed Central  Google Scholar 

Uppal K, Ma C, Go YM, Jones DP, Wren J. xMWAS: a data-driven integration and differential network analysis tool. Bioinformatics. 2018;34(4):701–2.

Article  PubMed  CAS  Google Scholar 

Terry MB, Phillips K-A, Daly MB et al. Cohort profile: the breast cancer prospective family study cohort (ProF-SC). Int J Epidemiol 2015:1–10.

Lundberg M, Eriksson A, Tran B, Assarsson E, Fredriksson S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res. 2011;39(15):e102.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Assarsson E, Lundberg M, Holmquist G, et al. Homogenous 96-Plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE. 2014;9(4):e95192.

Article  PubMed  PubMed Central  Google Scholar 

Lee A, Mavaddat N, Wilcox AN, et al. BOADICEA: a comprehensive breast cancer risk prediction modelincorporating genetic and nongenetic risk factors. Genet Sci. 2019;21(8):1708–18.

Google Scholar 

Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 2008;98.

Terry MB, Liao Y, Whittemore AS, et al. 10-year performance of four models of breast cancer risk: a validation study. Lancet Oncol. 2019;20(4):504–17.

Article  PubMed  Google Scholar 

Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996;93(1):136–40.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chang K, Pastan I. Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line. Int J Cancer. 1994;57(1):90–7.

Article  PubMed  CAS  Google Scholar 

Frierson HF, Moskaluk CA, Powell SM, et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol. 2003;34(6):605–9.

Article  PubMed  CAS  Google Scholar 

Parinyanitikul N, Blumenschein GR, Wu Y, et al. Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer. 2013;13(5):378–84.

Article  PubMed  CAS  Google Scholar 

Scholler N, Fu N, Yang Y, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in Sera from patients with ovarian carcinoma. Proc Natl Acad Sci. 1999;96(20):11531–6.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006;12(2):447–53.